Form 4: Director Linda A. Hill Receives Relay Therapeutics Options

Director Linda A. Hill was granted 32,947 stock options in Relay Therapeutics, Inc. as part of standard equity compensation.

Summary

• Director Linda A. Hill received a grant of 32,947 stock options for Relay Therapeutics, Inc. (RLAY) common stock.
• The options have an exercise price of $14.09 per share.
• The grant date for these options is June 9, 2026.
• The options are scheduled to vest in full on the earlier of the first anniversary of the grant date or the date of the next annual stockholders meeting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations.

Positives

• Equity-based compensation aligns the interests of the director with those of the shareholders.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• The value of the options is dependent on the future market performance of the company's common stock.

Future Outlook

The options vest in full on the earlier of June 9, 2027, or the date of the next annual meeting of stockholders.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are a standard corporate governance practice in the biotechnology sector to attract and retain board expertise.

Comparison to Industry Standards

• The vesting schedule of one year or the next annual meeting is consistent with standard director compensation practices for mid-cap biotech firms.

Stakeholder Impact

• Minor potential dilution for shareholders upon the eventual exercise of the options.

Next Steps

• Vesting of the options on the earlier of June 9, 2027, or the next annual stockholders meeting.

Key Dates

Keywords

Relay Therapeutics, RLAY, Form 4, Insider Trading, Stock Options, Director Compensation